Apatinib in patients with recurrent or metastatic thymic epithelial tumor: a single-arm, multicenter, open-label, phase II trial
文献类型：期刊论文
| 作者 | Song, Zhengbo1; Lou, Guangyuan7; Wang, Yina6; Yang, Zhiping5; Wang, Wenxian7; Ji, Yongling4; Chen, Shiqing3; Xu, Chunwei2; Hu, Xiao4; Zhang, Yiping7 |
| 刊名 | BMC MEDICINE
 |
| 出版日期 | 2022-05-10 |
| 卷号 | 20 |
| ISSN号 | 1741-7015 |
| 关键词 | Thymic epithelial tumors Apatinib Efficacy Toxicities |
| DOI | 10.1186/s12916-022-02361-w |
| 通讯作者 | Zhang, Yiping(yi_ping_zhang@163.com) |
| 英文摘要 | Background Thymic epithelial tumors (TETs) are rare malignancies and the treatment options are limited. We aimed to evaluate the efficacy and safety of apatinib, an angiogenesis inhibitor, in advanced TETs. Methods This was an open-label, single-arm, phase II trial at three centers in China. Patients with TET who had progressed after failure of at least one line of platinum-based chemotherapy were enrolled. Patients received apatinib 500 mg orally per day. The primary endpoint was objective response rate (ORR). Secondary endpoints were progression-free survival (PFS), overall survival (OS), disease control rate (DCR), and safety. Results From June 29, 2017, to April 18, 2019, 25 patients were enrolled. At data cut off (September 30, 2021), one patient achieved complete response, nine achieved partial response, and 11 achieved stable disease, with an ORR of 40% (95% CI 21-61%) and DCR of 84% (95% CI 64-95%). The median PFS was 9.0 (95% CI 5.4-12.6) months. The median OS was 24.0 (95% CI 8.2-39.8) months. All patients reported treatment-related adverse events (TRAEs). Grade 3 TRAEs occurred 26 times in 15 patients. No grade 4 or 5 toxicities occurred. Conclusions This is the first trial of apatinib for the treatment of TETs. Apatinib showed promising antitumor activity and the toxicities were tolerable and manageable. |
| WOS关键词 | ENDOTHELIAL-GROWTH-FACTOR ; DOUBLE-BLIND ; CARCINOMA ; CHEMOTHERAPY ; THYMOMA ; PEMBROLIZUMAB ; SORAFENIB ; RECEPTORS ; EFFICACY ; OUTCOMES |
| WOS研究方向 | General & Internal Medicine |
| 语种 | 英语 |
| 出版者 | BMC |
| WOS记录号 | WOS:000792624100001 |
| 源URL | [http://ir.hfcas.ac.cn:8080/handle/334002/130819]  |
| 专题 | 中国科学院合肥物质科学研究院 |
| 通讯作者 | Zhang, Yiping |
| 作者单位 | 1.Univ Chinese Acad Sci, Dept Clin Trial, Canc Hosp, Zhejiang Canc Hosp, Hangzhou 310022, Zhejiang, Peoples R China 2.Nanjing Univ, Jinling Hosp, Dept Resp Med, Sch Med, Nanjing 210002, Jiangsu, Peoples R China 3.3D Med Inc, Med Dept, Shanghai 201114, Peoples R China 4.Univ Chinese Acad Sci, Dept Radiotherapy Oncol, Canc Hosp, Zhejiang Canc Hosp, Hangzhou 310022, Zhejiang, Peoples R China 5.First Hosp Jiaxing, Dept Med Oncol, Jiaxing 314000, Zhejiang, Peoples R China 6.Zhejiang Univ, Affiliated Hosp 1, Coll Med, Dept Med Oncol, Hangzhou 310000, Zhejiang, Peoples R China 7.Univ Chinese Acad Sci, Canc Hosp, Dept Med Oncol, Zhejiang Canc Hosp, Hangzhou 310022, Zhejiang, Peoples R China |
| 推荐引用方式 GB/T 7714 | Song, Zhengbo,Lou, Guangyuan,Wang, Yina,et al. Apatinib in patients with recurrent or metastatic thymic epithelial tumor: a single-arm, multicenter, open-label, phase II trial[J]. BMC MEDICINE,2022,20. |
| APA | Song, Zhengbo.,Lou, Guangyuan.,Wang, Yina.,Yang, Zhiping.,Wang, Wenxian.,...&Zhang, Yiping.(2022).Apatinib in patients with recurrent or metastatic thymic epithelial tumor: a single-arm, multicenter, open-label, phase II trial.BMC MEDICINE,20. |
| MLA | Song, Zhengbo,et al."Apatinib in patients with recurrent or metastatic thymic epithelial tumor: a single-arm, multicenter, open-label, phase II trial".BMC MEDICINE 20(2022). |
入库方式： OAI收割
来源：合肥物质科学研究院
浏览0
下载0
收藏0
其他版本
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。